MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Home・Elenco Azioni・Savara Inc

Savara Inc

Chiusa

SettoreSettore sanitario

5.57 2.96

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.42

Massimo

5.64

Metriche Chiave
By Trading Economics
Entrata	-2.7M -32M
Dipendenti	70
EBITDA	-3.9M -33M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+87.73% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-71M 1B
Apertura precedente	2.61
Chiusura precedente	5.57

Notizie sul Sentiment di mercato

By Acuity

54%

46%

293 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

2.76 / 2.84 Supporto e resistenza

Savara Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 apr 2026, 22:56 UTC

Principali Notizie su Eventi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 apr 2026, 20:50 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 apr 2026, 23:55 UTC

Discorsi di Mercato

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 apr 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 apr 2026, 23:23 UTC

Principali Notizie su Eventi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 apr 2026, 23:07 UTC

Utili

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 apr 2026, 23:02 UTC

Principali Notizie su Eventi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 apr 2026, 22:39 UTC

Utili

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 apr 2026, 22:08 UTC

Discorsi di Mercato

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 apr 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 apr 2026, 21:31 UTC

Principali Notizie su Eventi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 apr 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 apr 2026, 20:38 UTC

Utili

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 apr 2026, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 apr 2026, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 apr 2026, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 apr 2026, 20:13 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 apr 2026, 20:07 UTC

Discorsi di Mercato

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 apr 2026, 20:07 UTC

Acquisizioni, Fusioni, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Confronto tra pari

Modifica del prezzo

Savara Inc Previsione

Obiettivo di Prezzo

By TipRanks

87.73% in crescita

Previsioni per 12 mesi

Media 10.25 USD 87.73%

Alto 11 USD

Basso 9 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Savara Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Savara Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

2.76 / 2.84Supporto e resistenza

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

293 / 349 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.